Cutaneous Lymphoma Clinical Management and Treatment Strategies

Cutaneous lymphomas comprise a heterogeneous group of extranodal non-Hodgkin lymphomas that manifest primarily in the skin. The most common subtypes, mycosis fungoides and Sézary syndrome, range from indolent patch-stage disease to aggressive leukaemic variants. Clinical management is tailored to disease stage, subtype and patient factors. Early-stage disease often responds to skin-directed therapies such as topical corticosteroids, retinoids, phototherapy and localised radiotherapy. Advanced or refractory cases require systemic agents, including interferons, retinoids, histone deacetylase inhibitors and monoclonal antibodies. Targeted small-molecule inhibitors against dysregulated signalling pathways have transformed treatment paradigms. Combination approaches—such as pairing immunomodulatory drugs with extracorporeal photopheresis—have demonstrated synergistic efficacy and durable remissions. For high-risk or relapsed patients, allogeneic stem-cell transplantation offers a potential curative option, albeit with significant toxicity. Novel strategies focus on reinvigorating anti-tumour immunity via checkpoint blockade, engineered cellular therapies and modulation of the tumour microenvironment. Ongoing efforts aim to integrate genomic and immune profiling into risk stratification, enabling personalised therapy and minimising overtreatment. Globally, variations in incidence and genetic drivers underscore the need for regionally adapted guidelines and access to emerging therapies.

Research from Nature Portfolio

A deep-learning analysis of skin biopsies in mycosis fungoides has revealed that upregulation of MHC class I on malignant T cells impairs natural killer cell-mediated cytotoxicity, creating an immune-evasive niche. Interruption of the MHC–NK inhibitory receptor axis in murine models restored NK-cell function and enhanced clearance of tumour cells, offering a preclinical blueprint for augmenting antibody-based therapies. Comprehensive multi-omics of primary cutaneous γδ T-cell lymphomas has defined discrete cell-of-origin signatures—epidermal Vδ1 versus panniculitic Vδ2 lineages—with shared recurrent mutations in JAK–STAT, MAPK and chromatin-modifier genes, highlighting actionable targets for precision treatment. In Sézary syndrome, integrated genome and exome sequencing uncovered frequent loss-of-function alterations in chromatin remodelers alongside activating mutations in JAK1, JAK3, STAT3 and STAT5B; primary cells harbouring JAK1 mutations exhibited sensitivity to pharmacological JAK inhibition, supporting clinical evaluation of targeted inhibitors in this aggressive leukaemic variant.

Cutaneous Lymphoma Clinical Management and Treatment Strategies publication trend

The graph below shows the total number of articles in cutaneous lymphoma clinical management and treatment strategies across all publications each year (not limited to Nature Index journals).

Technical terms

Cutaneous lymphoma: A malignancy of lymphoid cells presenting primarily in the skin.

Mycosis fungoides: The most common form of cutaneous T-cell lymphoma, typically indolent and presenting with patches or plaques.

Sézary syndrome: A leukemic variant of cutaneous T-cell lymphoma characterised by erythroderma and circulating malignant T cells.

Extracorporeal photopheresis (ECP): A therapy in which leukocytes are collected, exposed to a photosensitiser and ultraviolet light, then reinfused to induce immunomodulation.

Allogeneic stem-cell transplantation: Transfer of haematopoietic stem cells from a donor to a recipient to achieve graft-versus-tumour effects.

MHC class I (MHC-I): Cell-surface molecules that present antigenic peptides to cytotoxic T cells and can modulate natural killer cell activity.

Natural killer (NK) cell: An innate lymphoid cell capable of direct cytotoxicity against tumour or virus-infected cells.

JAK–STAT pathway: A signalling cascade activated by cytokines and growth factors, often dysregulated in lymphoid malignancies.

References

1. MHC-I upregulation safeguards neoplastic T cells in the skin against NK cell-mediated eradication in mycosis fungoides. Nature Communications (2024).
2. Dimethyl fumarate and extracorporeal photopheresis combination-therapy synergize in inducing specific cell death and long-term remission in cutaneous T cell lymphoma. Leukemia (2024).
3. Multi-omic profiling reveals the endogenous and neoplastic responses to immunotherapies in cutaneous T cell lymphoma. Cell Reports Medicine (2024).
4. Genomic analyses reveal recurrent mutations in epigenetic modifiers and the JAK–STAT pathway in Sézary syndrome. Nature Communications (2015).
5. Cellular origins and genetic landscape of cutaneous gamma delta T cell lymphomas. Nature Communications (2020).
6. Allogeneic stem-cell transplantation in patients with cutaneous lymphoma: updated results from a single institution. Annals of Oncology (2015).